ADVERTISEMENT

404

Not Found

Is this what you were looking for?

templates trackable display blog jsp

How to track a stem cell
Andrea Gawrylewski | Apr 30, 2008 | 2 min read
Before therapies using human embryonic stem cells can be approved by the Food and Drug Administration, researchers will have to answer one key question: where do the cells go when they are injected into the patient? During an FDA meeting earlier this linkurl:month;http://www.the-scientist.com/templates/trackable/display/blog.jsp?type=blog&o_url=blog/display/54544&id=54544 on the safety of embryonic stem cell therapies, the agency grappled with the issues of tracking stem cells in vivo. Regardl
Can publishers and NIH make OA work?
Andrea Gawrylewski | Mar 6, 2008 | 2 min read
The April 7 deadline is rapidly approaching for submitting all publications based on NIH-funded work to PubMed Central. But some publishers are still grumbling about how the NIH plans to implement the public access mandate, which was put in place in linkurl:January.;http://www.the-scientist.com/blog/display/54028/ linkurl:Last month,;http://www.the-scientist.com/blog/display/54372/ Pennsylvania Senator Arlen Specter asked NIH director Elias Zerhouni in a letter whether the NIH had adequately di
Crowdsourcing for science?
Alison McCook | Feb 19, 2008 | 2 min read
Last night, I and other attendees of the Knight Science Journalism Fellowships 25th Anniversary Symposium in Boston were introduced to an interesting idea, courtesy of Clive Thompson, science writer extraordinaire for Wired and other outlets: linkurl:Write blogs;http://www.collisiondetection.net/ to get ideas. It's a basic concept. Thompson -- a surprisingly dapper (for a writer), well-coiffed, quick-talking presenter -- explained that he constantly feeds his blog, collisiondetection.net, becau
Obama to lift stem cell ban?
Andrea Gawrylewski | Nov 9, 2008 | 1 min read
US President-elect Barack Obama is already considering a lift on the current restrictions on embryonic stem cell research, according to a member of Obama's transition team. Yesterday, John Podesta, one of the senior members of Obama's transition team and the previous chief of staff for Bill Clinton, told Fox News Sunday that the transition team is already considering lifting current linkurl:limits on stem cell research,;http://www.the-scientist.com/article/display/53224/ and how Obama can lift
Bluesens
Bluesens | Jan 12, 2009 | 2 min read
Bluesens Gas analyser for bioprocessing BCpreFerm for measuring CO2 and O2 on flasks and fermenters. lueSens gas sensor GmbH develops and markets FDA compliant PAT (process analytical technology) conform sensors for the detection and analysis of many gases, including CO2 and O2. Founded in 2001 as a specialist for gas analysis in bioprocessing, Blue- Sens is now established as the market leader, supplying sensors worldwide. Applications
It's all about Cells
Miltenyi Biotec | Jan 12, 2009 | 2 min read
It's all about cells Miltenyi Biotec products and services benefit the biomedical research community worldwide In 1989, a success story began in Bergisch Gladbach near Cologne: MACS® Technology was developed, an efficient and reliable method to tag and separate cells magnetically. Since then, the Miltenyi Biotec team has grown to more than 1,100 employees. They produce and market over 1,400 products for the biomedical research community worldwide,
Solutions for megatrends
Wolfgang Plischke | Jan 12, 2009 | 3 min read
Solutions for megatrends Legislation should be forward-looking for all fields of biotechnology. By Wolfgang Plischke Opinion by Wolfgang Plischke North Rhine-Westphalia is already one of Germany's most important industrial biotechnology locations. The generous funding provided by the state government for biotechnological research will be a key factor in enhancing the location's attractiveness in the future. Related Articles Pride and Pio
The Biocampus Cologne
The Biocampus Cologne | Jan 12, 2009 | 3 min read
The Biocampus Cologne Area of the future Companies need spatial perspectives to grow. Founders need a location, where the industry's knowledge is concentrated. Become a part of the industry of the future, biotechnology and life sciences, on the BioCampus Cologne, a top class location in the heart of Europe. The BioCampus Cologne is developing into a motor of innovation and one of the largest biotechnology parks in Germany. At the centre of the idea a
Two sides of a coin
Peer Schatz | Jan 12, 2009 | 3 min read
Two sides of a coin Local support and global outlook are an unbeatable combination. By Peer Schatz Opinion by Peer Schatz Qiagen started out in 1984 as a university spin-off. The idea was to revolutionize sample preparation and, in doing so, to transform molecular biology as a whole. Twenty-five years later we employ 3,000 at 30 locations worldwide, and in many people's eyes Qiagen is the epitome of the successful pairing of science and busi
Come Together
Manfred Kircher | Jan 12, 2009 | 3 min read
Come together CLIB2021 aspires to become Europe's leading industrial biotechnology cluster. By Manfred Kircher Opinion by Manfred Kircher Industrial biotechnology is crucial to the future economy and to the health of the planet. It utilizes renewable resources and develops novel materials and active substances for almost all markets and areas of life. It provides opportunities to innovate both process and product in many fields. For exampl

Run a Search

ADVERTISEMENT